PE123799A1 - Composiciones insolubles de insulina - Google Patents

Composiciones insolubles de insulina

Info

Publication number
PE123799A1
PE123799A1 PE1998000996A PE00099698A PE123799A1 PE 123799 A1 PE123799 A1 PE 123799A1 PE 1998000996 A PE1998000996 A PE 1998000996A PE 00099698 A PE00099698 A PE 00099698A PE 123799 A1 PE123799 A1 PE 123799A1
Authority
PE
Peru
Prior art keywords
insulin
protein
human insulin
acid
protamine
Prior art date
Application number
PE1998000996A
Other languages
English (en)
Inventor
Mark Laurence Brader
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE123799A1 publication Critical patent/PE123799A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

CARACTERIZADA PORQUE COMPRENDE: a)UNA PROTEINA DERIVATIZADA, COMO INSULINA, ANALOGO DE INSULINA Y PROINSULINA COMO desThr(B30)-INSULINA HUMANA, LysB28,ProB29-INSULINA HUMANA, AspB28-INSULINA HUMANA; ACILADA POR UN ACIDO GRASO SELECCIONADO DE ACIDO n-HEXANOICO, ACIDO n-HEPTANOICO, ACIDO n-OCTANOICO, ENTRE OTROS; EN EL GRUPO LysB29-N�-AMINO DE LA INSULINA; b)UN COMPUESTO COMPLEJANTE, COMO PROTAMINA UTILIZANDOSE DE 0,15 mg A 0,5 mg POR 3,5 mg DE PROTEINA; c)UN COMPUESTO ESTABILIZADOR DE HEXAMEROS COMO UN CONSERVANTE FENOLICO, EN PROPORCION QUE FACILITE LA FORMACION DE LA CONFORMACION HEXAMERA R6; d)UN CATION METALICO DIVALENTE COMO ZINC UTILIZANDO 0,3 MOLES A 0,7 MOLES POR MOL DE PROTEINA; LA COMPOSICION ES UN MICROCRISTAL EN FORMA DE BARRAS, PRECIPITADO AMORFO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. TAMBIEN SE REFIERE A UNA FORMULACION EN SUSPENSION QUE COMPRENDE: a)FASE INSOLUBLE COMPRENDE LA PROTEINA DERIVATIZADA; b)UNA FASE DE SOLUCION COMPRENDE AGUA, UN CONSERVANTE FENOLICO, UN TAMPON, UN AGENTE DE ISOTONICIDAD, ZINC, PROTAMINA
PE1998000996A 1997-10-24 1998-10-22 Composiciones insolubles de insulina PE123799A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6310497P 1997-10-24 1997-10-24
US8893098P 1998-06-11 1998-06-11

Publications (1)

Publication Number Publication Date
PE123799A1 true PE123799A1 (es) 1999-12-13

Family

ID=26743043

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000996A PE123799A1 (es) 1997-10-24 1998-10-22 Composiciones insolubles de insulina

Country Status (21)

Country Link
US (3) US6268335B1 (es)
EP (1) EP1039920A4 (es)
JP (2) JP2001521006A (es)
KR (1) KR20010024556A (es)
CN (1) CN1276731A (es)
AR (1) AR020047A1 (es)
AU (2) AU747926B2 (es)
BR (1) BR9813111A (es)
CA (2) CA2306905A1 (es)
CO (1) CO4970769A1 (es)
EA (1) EA200000453A1 (es)
HR (1) HRP20000236A2 (es)
HU (1) HUP0004169A3 (es)
ID (1) ID24890A (es)
IL (1) IL134901A0 (es)
NO (1) NO20002038L (es)
PE (1) PE123799A1 (es)
PL (1) PL340255A1 (es)
SV (1) SV1998000125A (es)
TR (1) TR200001050T2 (es)
WO (2) WO1999021573A1 (es)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
CO4970787A1 (es) * 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US7169889B1 (en) 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US20030054015A1 (en) * 2000-12-25 2003-03-20 Shinichiro Haze Sympathetic-activating perfume composition
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US20020155614A1 (en) * 2001-02-21 2002-10-24 Tomlinson Andrew J. Peptide esterification
US6835802B2 (en) 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7713932B2 (en) 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
EP1432430A4 (en) * 2001-08-28 2006-05-10 Lilly Co Eli PREMIXTURES OF GLP-1 AND BASALINSULIN
US7312192B2 (en) * 2001-09-07 2007-12-25 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7196059B2 (en) 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) * 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7166571B2 (en) * 2001-09-07 2007-01-23 Biocon Limited Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US6913903B2 (en) 2001-09-07 2005-07-05 Nobex Corporation Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
US20030095928A1 (en) * 2001-09-19 2003-05-22 Elan Pharma International Limited Nanoparticulate insulin
WO2003053460A1 (en) * 2001-12-19 2003-07-03 Eli Lilly And Company Crystalline compositions for controlling blood glucose
BR0215029A (pt) * 2001-12-20 2005-12-20 Lilly Co Eli Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
US7601688B2 (en) 2002-06-13 2009-10-13 Biocon Limited Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US20040038864A1 (en) * 2002-06-27 2004-02-26 Per Balschmidt Use of dimethyl sulfone as isotonicity agent
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
JP2006519791A (ja) * 2003-03-13 2006-08-31 ノボ　ノルディスク　アクティーゼルスカブ 新規なｎｐｈインスリン製剤
US20050054818A1 (en) * 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
US20060241019A1 (en) * 2003-07-25 2006-10-26 Bridon Dominique P Long lasting insulin derivatives and methods thereof
WO2005012347A2 (en) 2003-08-05 2005-02-10 Novo Nordisk A/S Novel insulin derivatives
AU2004295023A1 (en) 2003-12-03 2005-06-16 Novo Nordisk A/S Single-chain insulin
PT1773878E (pt) * 2004-07-19 2015-06-05 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
EP1679065A1 (en) * 2005-01-07 2006-07-12 OctoPlus Sciences B.V. Controlled release compositions for interferon based on PEGT/PBT block copolymers
JP2008533100A (ja) * 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｐｅｇ化された単鎖インスリン
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
WO2007081824A2 (en) * 2006-01-06 2007-07-19 Case Western Reserve University Fibrillation resistant proteins
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US20100160209A1 (en) * 2006-05-10 2010-06-24 Smithkline Beecham Corporation Composition and Method for Increasing Cell Permeability of a Compound
WO2007135118A1 (en) * 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
PL2074141T3 (pl) 2006-09-22 2017-02-28 Novo Nordisk A/S Analogi insuliny oporne na proteazę
ES2554773T3 (es) 2006-10-04 2015-12-23 Case Western Reserve University Insulina y análogos de la insulina resistentes a la fibrilación
JP5496082B2 (ja) 2007-04-30 2014-05-21 ノボ・ノルデイスク・エー／エス タンパク質組成物を乾燥させる方法、乾燥タンパク質組成物、及び乾燥タンパク質を含有する薬学的組成物
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
CA2695970A1 (en) * 2007-08-15 2009-02-19 Novo Nordisk A\S Insulin analogues with an acyl and aklylene glycol moiety
NZ585135A (en) 2007-10-16 2012-08-31 Biocon Ltd An orally administerable solid pharmaceutical composition comprising in-105 and a process thereof
DE102008003566A1 (de) * 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
AU2009203810B2 (en) * 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
NZ586590A (en) 2008-01-09 2012-06-29 Sanofi Aventis Deutschland Insulin analogues or derivatives having an extremely delayed time-action profile
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
WO2009129250A2 (en) * 2008-04-14 2009-10-22 Case Western Reserve University Meal-time insulin analogues of enhanced stability
KR20110021758A (ko) * 2008-04-22 2011-03-04 케이스 웨스턴 리저브 유니버시티 이형체-특이적 인슐린 유사체
KR20120129875A (ko) 2008-07-31 2012-11-28 케이스 웨스턴 리저브 유니버시티 염소화 아미노산을 갖는 인슐린 유사체
US9200053B2 (en) 2008-07-31 2015-12-01 Case Western Reserve University Insulin analogues containing penta-fluoro-Phenylalanine at position B24
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
EP2391217A4 (en) 2009-01-28 2015-05-20 Smartcells Inc SYNTHETIC CONJUGATES AND ITS USE
SG193837A1 (en) 2009-01-28 2013-10-30 Smartcells Inc Conjugate based systems for controlled drug delivery
US20100198188A1 (en) * 2009-02-05 2010-08-05 Abbott Diabetes Care Inc. Devices and Methods for Metering Insoluble Active Agent Particles
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc TERMINAL-FUNCTIONALIZED CONJUGATES AND THEIR USE
WO2011003820A1 (de) * 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Hitze- und schüttelstabile insulinzubereitungen
EP2451471A1 (de) * 2009-07-06 2012-05-16 Sanofi-Aventis Deutschland GmbH Langsamwirkende insulinzubereitungen
US8399407B2 (en) * 2009-09-17 2013-03-19 Case Western Reserve University Non-standard insulin analogues
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
JP5832439B2 (ja) 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物
EP2504019A2 (en) 2009-11-25 2012-10-03 ArisGen SA Mucosal delivery composition comprising a peptide complexed with a crown compound and/or a counter ion
NZ600477A (en) 2009-12-11 2014-07-25 Univ Case Western Reserve Insulin analogues with chlorinated amino acids
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
CN104693302A (zh) * 2010-06-23 2015-06-10 诺沃—诺迪斯克有限公司 包含额外的二硫键的胰岛素衍生物
CN103179978A (zh) 2010-08-30 2013-06-26 赛诺菲-安万特德国有限公司 Ave0010用于制造供治疗2型糖尿病用的药物的用途
JP6049625B2 (ja) 2010-10-27 2016-12-21 ノヴォ ノルディスク アー／エス 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012171994A1 (en) 2011-06-15 2012-12-20 Novo Nordisk A/S Multi substituted insulins
WO2013030160A1 (en) 2011-08-29 2013-03-07 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
CA2870313A1 (en) 2012-04-11 2013-10-17 Novo Nordisk A/S Insulin formulations
EP2925345B1 (en) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
SG11201506888VA (en) 2013-04-03 2015-09-29 Sanofi Sa Treatment of diabetes mellitus by long-acting formulations of insulins
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
CN105636979B (zh) 2013-10-07 2020-01-10 诺和诺德股份有限公司 胰岛素类似物的新衍生物
US9895424B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
EP3091995B1 (en) 2014-01-09 2024-03-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
JP6735674B2 (ja) 2014-01-09 2020-08-05 サノフイＳａｎｏｆｉ インスリンアスパルトの安定化された医薬製剤
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
CA2957714A1 (en) * 2014-08-11 2016-02-18 Albany Medical College Myristoylated leptin-related peptides and uses thereof
US10392429B2 (en) 2014-10-06 2019-08-27 Case Western Reserve University Biphasic single-chain insulin analogues
MA41138B1 (fr) 2014-12-12 2023-07-31 Sanofi Aventis Deutschland Formulation à rapport fixe d'insuline glargine/lixisenatide
CN105884879A (zh) * 2015-01-26 2016-08-24 漳州博欣生物技术有限公司 一种胰岛素类似物的化学合成方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN108026157B (zh) * 2015-08-25 2022-11-25 诺和诺德股份有限公司 新型胰岛素衍生物及其医学用途
CN105597087B (zh) * 2016-01-06 2019-04-26 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
CA3035850A1 (en) 2016-09-06 2018-03-15 Chemical & Biopharmaceutical Laboratories Of Patras S.A. Proinsulin derivatives
JP2020504714A (ja) 2016-12-05 2020-02-13 ニューリタス リミテッド ペプチドｗｋｄｅａｇｋｐｌｖｋを含む組成物
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
US20180169190A1 (en) 2016-12-16 2018-06-21 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US20200147215A1 (en) * 2017-04-24 2020-05-14 Simon H. Friedman Drug conjugates with photocleavable solubility modulators
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل
US11413352B2 (en) 2017-12-18 2022-08-16 Merck, Sharp & Dohme LLC Conjugate based systems for controlled insulin delivery
WO2019125878A1 (en) 2017-12-18 2019-06-27 Merck Sharp & Dohme Corp. Conjugate based systems for controlled insulin delivery
WO2019222221A1 (en) * 2018-05-14 2019-11-21 Dance Biopharm Inc. Insulin formulations for reconstitution into high concentration liquid solutions
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
BR112021011156A2 (pt) 2018-12-11 2021-10-26 Sanofi Conjugados de insulina
CN110063932A (zh) * 2019-04-12 2019-07-30 浙江大学 一种多肽蛋白类药物的缓释组合物制剂及其制备方法
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
MY208364A (en) 2019-12-11 2025-05-01 Novo Nordisk As Novel insulin analogues and uses thereof
BR112022019687A2 (pt) 2020-03-31 2022-12-20 Protomer Tech Inc Conjugados para responsividade seletiva a dióis vicinais
IL297976A (en) * 2020-05-15 2023-01-01 Lilly Co Eli Extended time action acylated insulin compounds
MX2023005935A (es) 2020-11-19 2023-05-29 Protomer Tech Inc Compuestos aromaticos que contienen boro y analogos de insulina.
WO2022125587A1 (en) * 2020-12-07 2022-06-16 Case Western Reserve University Acylated single-chain insulin analogues
IL317049A (en) 2022-05-18 2025-01-01 Protomer Tech Inc Aromatic boron-containing compounds and related insulin analogs

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2801953A (en) 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US2849370A (en) 1953-06-04 1958-08-26 Novo Terapeutisk Labortorium A Injectable insulin preparations with protracted effect and process of producing same
US3102077A (en) 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
US3060093A (en) 1957-07-18 1962-10-23 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form and method of preparation
DE1793517C3 (de) 1968-09-28 1974-12-05 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt N(Al),N(B29>Bis-(tert.-butyloxycarbonyl)-insulin und Verfahren zu seiner Herstellung
US3950517A (en) 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
GB1381274A (en) 1971-01-28 1975-01-22 Nat Res Dev Insulin derivatives
US3868358A (en) 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US3865325A (en) 1971-07-02 1975-02-11 Dylaker Computer Systems Inc Flexible tape reel
US3907763A (en) 1972-03-01 1975-09-23 Bayer Ag Insulin derivatives crosslinked by a dicarboxylic acid moiety
US4183849A (en) 1975-01-15 1980-01-15 Nordisk Insulinlaboratorium Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect
JPS55138391A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd New synthetic method of peptide derivative
JPS55138393A (en) 1979-04-13 1980-10-29 Shionogi & Co Ltd Semisynthesis of insulin
IE50892B1 (en) 1980-02-11 1986-08-06 Novo Industri As Process for preparing insulin esters
DE3101382A1 (de) 1981-01-17 1982-09-02 Hoechst Ag, 6000 Frankfurt "verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten"
DK353781A (da) 1981-08-10 1983-02-11 Novo Industri As Fremgangsmaade til fremstilling af insulinderivater
AU551174B2 (en) 1981-09-15 1986-04-17 Nordisk Insulinlaboratorium Enzymatic preparation of human insulin or b-30 esters thereof
DE3326473A1 (de) 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
US4946828A (en) * 1985-03-12 1990-08-07 Novo Nordisk A/S Novel insulin peptides
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
KR900701842A (ko) 1988-07-20 1990-12-04 헨리 브뢰늄 인간 인슐린 동족체와 그를 포함하는 제제
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
DK134189D0 (da) 1989-03-20 1989-03-20 Nordisk Gentofte Insulinforbindelser
WO1995000550A1 (en) 1993-06-21 1995-01-05 Novo Nordisk A/S Aspb28 insulin crystals
DK72793D0 (da) * 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
EP0792290B1 (en) * 1993-09-17 2001-08-29 Novo Nordisk A/S Acylated insulin
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5597893A (en) 1994-10-31 1997-01-28 Eli Lilly And Company Preparation of stable insulin analog crystals
US5646242A (en) * 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
HUP9800523A3 (en) 1995-03-17 1998-09-28 Novo Nordisk As Insulin derivatives
US5700904A (en) * 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
US5877153A (en) 1996-06-11 1999-03-02 Commonwealth Biotechnologies Inc. Heparin-binding peptides
JP4472027B2 (ja) 1996-06-20 2010-06-02 ノボ ノルディスク アクティーゼルスカブ 炭水化物含有インスリン製剤
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
ATE294189T1 (de) 1997-02-07 2005-05-15 Novo Nordisk As Kristallisation von proteinen
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.

Also Published As

Publication number Publication date
CA2306905A1 (en) 1999-05-06
US6268335B1 (en) 2001-07-31
EA200000453A1 (ru) 2000-10-30
SV1998000125A (es) 1999-05-24
HUP0004169A3 (en) 2001-06-28
NO20002038D0 (no) 2000-04-18
CN1276731A (zh) 2000-12-13
TR200001050T2 (tr) 2000-08-21
AR020047A1 (es) 2002-04-10
IL134901A0 (en) 2001-05-20
US20010036916A1 (en) 2001-11-01
HUP0004169A2 (hu) 2001-05-28
WO1999021578A1 (en) 1999-05-06
NO20002038L (no) 2000-06-26
WO1999021573A1 (en) 1999-05-06
ID24890A (id) 2000-08-31
US6465426B2 (en) 2002-10-15
AU1111799A (en) 1999-05-17
EP1039920A1 (en) 2000-10-04
JP2001521004A (ja) 2001-11-06
PL340255A1 (en) 2001-01-29
BR9813111A (pt) 2000-08-15
AU747926B2 (en) 2002-05-30
JP2001521006A (ja) 2001-11-06
AU1116699A (en) 1999-05-17
EP1039920A4 (en) 2003-05-28
US20020082199A1 (en) 2002-06-27
CO4970769A1 (es) 2000-11-07
CA2306877A1 (en) 1999-05-06
HRP20000236A2 (en) 2001-02-28
KR20010024556A (ko) 2001-03-26

Similar Documents

Publication Publication Date Title
PE123799A1 (es) Composiciones insolubles de insulina
PE20000106A1 (es) Composiciones insolubles para controlar la glucosa en la sangre
US20080154210A1 (en) Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds
DE3837825A1 (de) Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
AR018526A1 (es) COMPOSICION FARMACEUTICA NO LIOFILIZADA EN FORMA DE SOLUCIoN QUE COMPRENDE LA HORMONA PARATIROIDEA HUMANA, PROCESO PARA PREPARA UN FRASCO O CARTUCHO QUE LA CONTIENE, PROCESO PARA PREPARAR DICHA COMPOSICIoN, FRASCO O CARTUCHO QUE CONTIENE LA COMPOSICIoN Y USO DE LA MISMA PARA LA FABRICACIoN DE UN MED
DE69431071D1 (de) Zusammensetzung für lokale freigabe von zytostatika
RU98112109A (ru) Производное инсулина или его физиологически приемлемая соль, предшественник производного инсулина, днк-последовательность, кодирующая предшественник, вектор экспрессии, содержащий упомянутую днк-последовательность, субстрат, трансформированный упомянутым вектором экспрессии, и фармацевтическая композиция с понижающей, соответственно регулирующей уровень глюкозы в крови эффективностью
JP2007531767A5 (es)
ES2061460T3 (es) Un composicion detergente liquida.
UA74347C2 (uk) Безводна або майже безводна, стабільна рідка композиція
CA2566354C (en) A mixture for transdermal delivery of low and high molecular weight compounds
ES2236525T3 (es) Antarticina-nf3 para el tratamiento y re-epitelizacion.
CA2652752A1 (en) Pharmaceutical formulations for iontophoretic drug delivery
CN103932975A (zh) 一种外用水凝胶组合物及其制剂
ES2861052T3 (es) Composición tópica que comprende oxibutinina para el tratamiento de la hiperhidrosis
ES8700054A1 (es) Procedimiento de obtencion de germicidas a base de acidos clorhidrico y fosforico.
GB2356347B (en) Pharmaceutical compositions and their use
ATE345777T1 (de) Biologisch aktive zusammensetzung
RU2004119850A (ru) Композиция на основе сложного диосгенина для топического нанесения
DE2917790A1 (de) Pharmazeutische verbindung mit verbesserter schleimloesender und die schleimsekretionen verfluessigender wirkung
CA2986295C (en) Use of potassium hydroxide in the treatment of actinic keratosis
IE38514B1 (en) Improvements in or relating to insulin preparations
DK138191D0 (da) Salicylsyreholdigt middel til behandling af afskallende hudlidelser
GB1441364A (en) Iodophor compositions
CA1060800A (en) Anti-inflammatory composition containing potassium chloride

Legal Events

Date Code Title Description
FC Refusal